Evidence map›Paper›PMID 37353944›Full record

ArticleCNS neuroscience & therapeutics2023

Cdk5 phosphorylation-dependent C9orf72 degradation promotes neuronal death in Parkinson's disease models.

Xingfeng Xu, Mao Li, Yan Su, Qi Wang, Peifang Qin, Haitao Huang, Yuting Zhang, Yali Zhou, Jianguo Yan

Open access · goldAbstract read
In one paragraph

Article in CNS neuroscience & therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 citations in OpenAlex.

  1. Association between C9orf72 G4C2 repeat length and idiopathic Parkinson's disease in a Turkish cohort.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  2. The Recycling Endosomal (NaActa physiologica (Oxford, England) · 2026
    Article
  3. Review
  4. CDK5: Insights into its roles in diseases.Molecular biology reports · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xingfeng XuDepartment of Physiology, Guilin Medical University, Guilin, Guangxi, China.
Mao LiDepartment of Physiology, Guilin Medical University, Guilin, Guangxi, China.
Yan SuDepartment of Physiology, Guilin Medical University, Guilin, Guangxi, China.
Qi WangDepartment of Physiology, Guilin Medical University, Guilin, Guangxi, China.
Peifang QinDepartment of Microbiology, Guilin Medical University, Guilin, Guangxi, China.
Haitao HuangDepartment of Microbiology, Guilin Medical University, Guilin, Guangxi, China.
Yuting ZhangDepartment of Microbiology, Guilin Medical University, Guilin, Guangxi, China.
Yali ZhouDepartment of Microbiology, Guilin Medical University, Guilin, Guangxi, China.
Jianguo YanDepartment of Physiology, Guilin Medical University, Guilin, Guangxi, China.ORCID 0000-0003-4601-4830
Guilin Medical University · CN

Funding

Guangxi Medical and health key cultivation discipline construction projectInnovation Project of Guangxi Graduate Education YCSW2023417National Natural Science Foundation of China 81860246:82160517Natural Science Foundation of Guangxi Province 2023GXNSFAA026213The Scientific Research and Technology Development Program of Guangxi AD18281009Thousands of Young and Middle-aged Backbone Teachers in Guangxi colleges and Universities Training Plan
6 · The paper itself

Abstract

aimsChromosome 9 open reading frame 72 (C9orf72) is one of the most dazzling molecules in neurodegenerative diseases, albeit that its role in Parkinson's disease (PD) remains unknown. This article aimed to explore the potential mechanism of C9orf72 involved in the pathogenesis of PD.

methodsThe expression and phosphorylation levels of C9orf72 were examined by Western blotting, RT-PCR, and immunoprecipitation using PD models. Multiple bioinformatics software was used to predict the potential phosphorylation sites of C9orf72 by Cdk5, followed by verification of whether Cdk5-inhibitor ROSCOVITINE could reverse the degradation of C9orf72 in PD. By constructing the sh-C9orf72-knockdown adenovirus and overexpressing the FLAG-C9orf72 plasmid, the effects of C9orf72 knockdown and overexpression, respectively, were determined. A short peptide termed Myr-C9orf72 was used to verify whether interfering with Cdk5 phosphorylation at the Ser9 site of the C9orf72 protein could alleviate autophagy disorder, neuronal death, and movement disorder in PD models.

resultsThe expression level of the C9orf72 protein was significantly reduced, albeit the mRNA expression was not changed in the PD models. Moreover, the phosphorylation level was enhanced, and its reduction was mainly degraded by the ubiquitin-proteasome pathway. The key nervous system kinase Cdk5 directly phosphorylated the S9 site of the C9orf72 protein, which promoted the degradation of the C9orf72 protein. The knockdown of C9orf72 aggravated autophagy dysfunction and increased neuronal loss and motor dysfunction in substantia nigra neurons of PD mice. The overexpression of C9orf72 alleviated autophagy dysfunction in PD neurons. Specifically, interference with Cdk5 phosphorylation at the S9 site of C9orf72 alleviated autophagy dysfunction, neuronal death, and motor dysfunction mediated by C9orf72 protein degradation during PD.

conclusionsCumulatively, our findings illustrate the importance of the role of C9orf72 in the regulation of neuronal death during PD progression via the Cdk5-dependent degradation.

Indexed as

Parkinson DiseaseAnimalsC9orf72 ProteinCell DeathCyclin-Dependent Kinase 5MiceNeuronsPhosphorylationC9orf72 ProteinC9orf72 protein, mouseCdk5 protein, mouseCyclin-Dependent Kinase 5C9orf72cyclin-dependent protein kinase 5Parkinson's diseaseprotein phosphorylationubiquitin-proteasome pathway

Identifiers

PMID37353944
PMCPMC10651984
OpenAlexW4381838842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.